GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response

Copyright © 2010 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 137(2010), 1 vom: 15. Okt., Seite 31-40
1. Verfasser: Chéramy, Mikael (VerfasserIn)
Weitere Verfasser: Skoglund, Camilla, Johansson, Ingela, Ludvigsson, Johnny, Hampe, Christiane S, Casas, Rosaura
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2010
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't Adjuvants, Immunologic Alum Compounds Antibodies Autoantibodies C-Peptide ICA512 autoantibody Immune Sera mehr... Immunoglobulin G Tetanus Toxoid aluminum sulfate 34S289N54E Immunoglobulin E 37341-29-0 Glutamate Decarboxylase EC 4.1.1.15 glutamate decarboxylase 2
Online verfügbar Volltext